Ocuphire Pharma, Inc.

Restoring Vision and Clarity

Ocuphire Pharma is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders.

SEE WHO WE ARE

CORPORATE PRESENTATION

A Clear-sighted Product Pipeline

Nyxol®

Targets: Pharmacologically-induced Mydriasis, Presbyopia, and Dim Light or Night Vision Disturbances

Nyxol® Eye Drops is a once-daily preservative-free eye drop formulation designed to reduce pupil size and improve visual acuity.

View Nyxol

APX3330

Targets: Diabetic Retinopathy and Diabetic Macular Edema

APX3330 is a twice-a-day oral tablet, designed to inhibit angiogenesis and inflammatory pathways relevant to retinal and choroidal vascular diseases.

View APX3330

Our Clinical Trials

Ocuphire Pharma plans to readout 4 clinical trials with a potential NDA filing for the RM indication in 2022.

View Clinical Trials

Latest News

Ocuphire Announces Positive Topline Results from LYNX-1 Phase 3 Trial Evaluating Nyxol® Eye Drops for Night Vision Disturbances

Ocuphire Pharma Announces Financial Results for First Quarter 2022 and Provides Corporate Update

View Release

Ocuphire Pharma Announces Upcoming Presentations at the Retina World Congress, Clinical Trials at the Summit, and the H.C. Wainwright Global Investment Conference

View Release

Ocuphire Completes Last Clinical Trial Supporting the Planned 2022 NDA Submission with the Announcement of Positive Results from MIRA-4 Pediatric Safety Trial Evaluating Nyxol® for Reversal of Mydriasis

View Release

Stock Snapshot

View Investor Relations